Do Statins Have Antidepressant Effects? (Q39183235)

9 September 2017

Do Statins Have Antidepressant Effects? (English)

1 reference

9 September 2017

Ole Köhler-Forsberg

1

0 references

Søren Dinesen Østergaard

object named as

Søren Dinesen Østergaard

series ordinal

4

0 references

Christiane Gasse

object named as

Christiane Gasse

series ordinal

2

0 references

Michael Berk

object named as

Michael Berk

series ordinal

3

0 references

publication date

16 March 2017

1 reference

9 September 2017

1 reference

9 September 2017

31

1 reference

9 September 2017

5

1 reference

9 September 2017

335-343

1 reference

https://scigraph.springernature.com/pub.10.1007/s40263-017-0422-3

9 September 2017

0 references

cites work

Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0422-3

What did STAR*D teach us? Results from a large-scale, practical, clinical trial for patients with depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0422-3

A meta-analysis of cytokines in major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0422-3

From inflammation to sickness and depression: when the immune system subjugates the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0422-3

The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0422-3

Effect of anti-inflammatory treatment on depression, depressive symptoms, and adverse effects: a systematic review and meta-analysis of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0422-3

Statins as potential therapeutic agents in neuroinflammatory disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0422-3

Statins use and risk of depression: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0422-3

Statin and Aspirin Use and the Risk of Mood Disorders among Men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0422-3

The Effect of Concomitant Treatment With SSRIs and Statins: A Population-Based Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0422-3

Simvastatin treatment exerts antidepressant-like effect in rats exposed to chronic mild stress.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0422-3

Statins for the treatment of depression: A meta-analysis of randomized, double-blind, placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0422-3

Innate and adaptive immune responses can be beneficial for CNS repair

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0422-3

Cross-talk between neural stem cells and immune cells: the key to better brain repair?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0422-3

The macrophage theory of depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0422-3

Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0422-3

Type 1 diabetes mellitus and major depressive disorder: evidence for a biological link

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0422-3

Depression in rheumatoid arthritis: a systematic review of the literature with meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0422-3

Autoimmune diseases and severe infections as risk factors for mood disorders: a nationwide study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0422-3

Elevated C-reactive protein levels, psychological distress, and depression in 73, 131 individuals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0422-3

Atopic disorders and depression: findings from a large, population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0422-3

The plasma levels of various cytokines are increased during ongoing depression and are reduced to normal levels after recovery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0422-3

Association of high-sensitivity C-reactive protein with de novo major depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0422-3

CRP, IL-6 and depression: a systematic review and meta-analysis of longitudinal studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0422-3

Association of serum interleukin 6 and C-reactive protein in childhood with depression and psychosis in young adult life: a population-based longitudinal study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0422-3

Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0422-3

Antidepressant pretreatment for the prevention of interferon alfa-associated depression: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0422-3

A critical review of human endotoxin administration as an experimental paradigm of depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0422-3

The association between depressive and anxiety symptoms and bone mineral density in the general population: the HUNT Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0422-3

Depression is a risk factor for incident coronary heart disease in women: An 18-year longitudinal study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0422-3

Inflammation and Specific Symptoms of Depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0422-3

White blood cell count correlates with mood symptom severity and specific mood symptoms in bipolar disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0422-3

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0422-3

Competitive inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase by ML-236A and ML-236B fungal metabolites, having hypocholesterolemic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0422-3

Statins for Prevention of Cardiovascular Disease in Adults: Evidence Report and Systematic Review for the US Preventive Services Task Force

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0422-3

Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0422-3

Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0422-3

Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0422-3

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0422-3

Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0422-3

Clinical relevance for lowering C-reactive protein with statins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0422-3

Associations between cardiovascular disease risk factors and IL-6 and hsCRP levels in the elderly.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0422-3

C-reactive protein levels and genetic variants of CRP as prognostic markers for combined cardiovascular endpoint (cardiovascular death, death from stroke, myocardial infarction, and stroke/TIA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0422-3

Association of nitrotyrosine levels with cardiovascular disease and modulation by statin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0422-3

Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0422-3

Statins and biomarkers of inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0422-3

Risk of new-onset diabetes associated with statin use

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0422-3

Interpretation of the evidence for the efficacy and safety of statin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0422-3

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0422-3

The effect of statins on average survival in randomised trials, an analysis of end point postponement

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0422-3

Inflammation and depression: combined use of selective serotonin reuptake inhibitors and NSAIDs or paracetamol and psychiatric outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0422-3

Effect of celecoxib add-on treatment on symptoms and serum IL-6 concentrations in patients with major depressive disorder: randomized double-blind placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0422-3

Protocol and rationale-the efficacy of minocycline as an adjunctive treatment for major depressive disorder: a double blind, randomised, placebo controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0422-3

A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0422-3

The efficacy of adjunctive N-acetylcysteine in major depressive disorder: a double-blind, randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0422-3

Augmentation of fluoxetine with lovastatin for treating major depressive disorder, a randomized double-blind placebo controlled-clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0422-3

In a randomized, double-blind clinical trial, adjuvant atorvastatin improved symptoms of depression and blood lipid values in patients suffering from severe major depressive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0422-3

Simvastatin as an adjuvant therapy to fluoxetine in patients with moderate to severe major depression: A double-blind placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0422-3

Simvastatin versus atorvastatin for improving mild to moderate depression in post-coronary artery bypass graft patients: A double-blind, placebo-controlled, randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0422-3

The use of statins for the treatment of depression in patients with acute coronary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0422-3

Youth Depression Alleviation-Augmentation with an anti-inflammatory agent (YoDA-A): protocol and rationale for a placebo-controlled randomized trial of rosuvastatin and aspirin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0422-3

Obesity and the relationship with positive and negative affect

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0422-3

Statin use and risk of depression: a Swedish national cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0422-3

Hyperlipidemia, statin use and the risk of developing depression: a nationwide retrospective cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0422-3

A prospective study of statin use and poststroke depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0422-3

The impact of statins on psychological wellbeing: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0422-3

Statins and the risk of dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0422-3

Use of statins and risk of hospitalization with dementia: a Danish population-based case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0422-3

Psychologic disorders and statin use: a propensity score-matched analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0422-3

Cognitive decline and depressive symptoms in late-life are associated with statin use: evidence from a population-based study of Sardinian old people living in their own home.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0422-3

The relationship between statins and depression: a review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0422-3

No association between serum cholesterol and death by suicide in patients with schizophrenia, bipolar affective disorder, or major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0422-3

Neuropsychiatric adverse events associated with statins: epidemiology, pathophysiology, prevention and management.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0422-3

Selective serotonin reuptake inhibitor drug interactions in patients receiving statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0422-3

Improvement in symptoms of depression and in an index of life stressors accompany treatment of severe hypertriglyceridemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0422-3

Lipid-lowering drugs and the risk of depression and suicidal behavior

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0422-3

An inflammatory biomarker as a differential predictor of outcome of depression treatment with escitalopram and nortriptyline.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0422-3

The addition of depression to the Framingham Risk Equation model for predicting coronary heart disease risk in women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0422-3

Statins of different brain penetrability differentially affect CSF PLTP activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0422-3

Predictive analytics in mental health: applications, guidelines, challenges and perspectives.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0422-3

Seventeen years of statin pharmacogenetics: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0422-3

A genetic risk score is significantly associated with statin therapy response in the elderly population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0422-3

A genetic risk score is associated with statin-induced low-density lipoprotein cholesterol lowering

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0422-3

Pharmacogenetic determinants of statin-induced reductions in C-reactive protein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0422-3

Simvastatin inhibits the monocyte expression of proinflammatory cytokines in patients with hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0422-3

Low serum cholesterol and suicide

21 January 2018

1 reference

12 December 2020

Pharmacogenomics of statins: understanding susceptibility to adverse effects

1 reference

12 December 2020

Dose-dependent development of depressive symptoms during adjuvant interferon-{alpha} treatment of patients with malignant melanoma.

1 reference

12 December 2020

1 reference

12 December 2020

Interleukin (IL)-6, tumour necrosis factor alpha (TNF-α) and soluble interleukin-2 receptors (sIL-2R) are elevated in patients with major depressive disorder: a meta-analysis and meta-regression

1 reference

12 December 2020

Statins for the prevention of dementia

1 reference

12 December 2020

Statins for the primary prevention of cardiovascular disease

1 reference

12 December 2020

Premature mortality from coronary heart disease. The Framingham study

1 reference

12 December 2020

Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

1 reference

12 December 2020

Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators

1 reference

12 December 2020

Acute antidepressant and anxiolytic effects of simvastatin and its mechanisms in rats.

1 reference

12 December 2020

10.1007/S40263-017-0422-3

Identifiers

DOI

1 reference

release_q7jdrciufve7jipvsbmim5asty

9 September 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/q7jdrciufve7jipvsbmim5asty

24 November 2022

mapped directly with Wikidata item

PubMed ID

28303466

1 reference

PubMed ID

28303466